Literature DB >> 12377415

Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization.

Kotaro Kasahara1, Takahiro Taguchi, Ichiro Yamasaki, Masayuki Kamada, Kazunari Yuri, Taro Shuin.   

Abstract

In this study, we examined nine cases of advanced Japanese prostate cancer by comparative genomic hybridization (CGH) to detect chromosomal imbalances across the entire genome and to identify several new regions likely to contain genes important to the development and progression of this disease. These cases had been previously examined for numerical chromosomal aberrations by fluorescence in situ hybridization (FISH). By CGH, the following regions were found to be over-represented (gains), with fluorescence ratio values higher than the threshold: 4p, 6p, 8q, 11q, 12q, 15q, 16p, 17q, 20, and 21 (>4 cases); underrepresentation (losses) involved: 1q, 4q, 5q, 6q, 13q, 14q, and 22 (>4 cases). The shortest regions of overlap (SRO) of gains were noted at 8q24.1 through q24.3, 12q23, and 17q23 through q24 (>5 cases). The SRO of losses were seen at 5q14 through q21, 6q16.1 through q21, 13q21.3 through q22, and 14q21 (>5 cases). Notably, the gain of chromosomes 8 and 12 by CGH was in agreement with the FISH data, suggesting that the gain of chromosomes 8 and 12 may play an important role in prostate carcinogenesis. The genes on the SRO regions were also discussed in relation to oncogenes and bone metastases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377415     DOI: 10.1016/s0165-4608(02)00552-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  21 in total

1.  PROTEOME-3D: an interactive bioinformatics tool for large-scale data exploration and knowledge discovery.

Authors:  Deborah H Lundgren; Jimmy Eng; Michael E Wright; David K Han
Journal:  Mol Cell Proteomics       Date:  2003-09-07       Impact factor: 5.911

2.  A novel LZAP-binding protein, NLBP, inhibits cell invasion.

Authors:  Junhye Kwon; Hyun Jung Cho; Seung Hun Han; Jin Gu No; Jae Young Kwon; Hongtae Kim
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

4.  The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study.

Authors:  J Chaudhary; M Schmidt
Journal:  Chromosome Res       Date:  2006-07-12       Impact factor: 5.239

5.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

6.  Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells.

Authors:  Mohammad Javad Dehghan Esmatabadi; Baharak Farhangi; Maryam Montazeri; Hamideh Monfared; Roohollah Nakhaei Sistani; Majid Sadeghizadeh
Journal:  Iran J Basic Med Sci       Date:  2017-04       Impact factor: 2.699

Review 7.  Estrogen, male dominance and esophageal adenocarcinoma: is there a link?

Authors:  Huiqi Yang; Olga A Sukocheva; Damian J Hussey; David I Watson
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

Review 8.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

9.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 10.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.